Clinical Trial Update: Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) [NA]

View source ↗

Summary

A clinical trial is evaluating local targeted alpha emitter therapy using 225Ac-DOTA-SP (TAT) for newly diagnosed glioma (WHO grade 3-4) and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma

Drugs mentioned

• 225Ac-DOTA-SP (TAT) (Actinium-225-DOTA-SP)

Snippet

Sponsor: Medical University of Warsaw | Conditions: Glioblastoma, High-Grade Glioma (WHO III-IV) | NA | Status: RECRUITING